Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Dynavax Technologies
About
Dynavax Technologies is a biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.
- 501 - 1000
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- $40M
- Industries
- Biopharma,Biotechnology,Clinical Trials,Health Care,Medical Device
- Founded date
- Jan 1, 1996
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 29, 2014 | Debt Financing | $40M | 1 |
Hercules Capital
|
— | Detail |
| Apr 25, 2002 | Series D | $34.80M | 4 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Debt Financing |
|
|
— | Series D |
|
|
— | Series D |
|
|
— | Series D |
|
|
— | Series D |
